Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab

To investigate the possible correlation between the development of adverse events (AEs) and prognosis in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atez/Bev).

[1]  M. Kudo,et al.  Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib , 2022, Cancer medicine.

[2]  M. Kudo,et al.  Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice , 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

[3]  Y. Hiasa,et al.  Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis , 2022, Cancer medicine.

[4]  Y. Hiasa,et al.  Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study , 2022, Hepatology International.

[5]  Y. Hiasa,et al.  Neutrophil–lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis , 2022, European journal of gastroenterology & hepatology.

[6]  Y. Hiasa,et al.  Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis , 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

[7]  M. Kudo,et al.  Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis , 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

[8]  H. Koga,et al.  Adverse events as potential predictive factors of activity in advanced hepatocellular carcinoma patients treated with lenvatinib. , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[9]  M. Kudo,et al.  Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience , 2021, Cancer reports.

[10]  A. Cucchetti,et al.  Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison , 2021, Targeted Oncology.

[11]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[12]  T. Kawaguchi,et al.  Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study , 2020, Cancers.

[13]  J. Marrero,et al.  Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference , 2020, Hepatology.

[14]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[15]  K. Chayama,et al.  JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

[16]  D. Schadendorf,et al.  Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo , 2020, JAMA oncology.

[17]  Y. Hiasa,et al.  Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

[18]  L. Rimassa,et al.  Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. , 2019, Cancer treatment reviews.

[19]  D. Speiser,et al.  Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. , 2019, JAMA Oncology.

[20]  A. Alfranca,et al.  Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. , 2019, European journal of cancer.

[21]  R. Chiari,et al.  Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis , 2018, Journal of Cancer Research and Clinical Oncology.

[22]  H. Houchi,et al.  Hypertension and Proteinuria as Predictive Factors of Effects of Bevacizumab on Advanced Breast Cancer in Japan. , 2018, Biological and Pharmaceutical Bulletin.

[23]  M. Schlumberger,et al.  Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes , 2017, Endocrine.

[24]  S. Nomura,et al.  Retrospective analysis of bevacizumab‐induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer , 2016, Cancer medicine.

[25]  H. Toyoda,et al.  Impact of the branched‐chain amino acid to tyrosine ratio and branched‐chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis , 2015, Journal of gastroenterology and hepatology.

[26]  H. Christofk,et al.  Autocrine VEGF maintains endothelial survival through regulation of metabolism and autophagy , 2015, Journal of Cell Science.

[27]  W. Curran,et al.  Bevacizumab‐induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab , 2015, Cancer.

[28]  S. Kawasaki,et al.  Evidence‐based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH‐HCC Guidelines) , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[29]  Y. Imai,et al.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan , 2014, Liver Cancer.

[30]  R. Touyz,et al.  Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. , 2014, The Canadian journal of cardiology.

[31]  A. Danser,et al.  Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1 , 2013, Journal of hypertension.

[32]  G. Sledge,et al.  Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. , 2013, The oncologist.

[33]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[34]  S. Pignata,et al.  Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms. , 2012, Critical reviews in oncology/hematology.

[35]  E. Karapanagiotou,et al.  Bevacizumab-Induced Hypertension , 2011, BioDrugs.

[36]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[37]  H. Isoniemi,et al.  Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy , 2011, British Journal of Cancer.

[38]  Xiaoyuan Chen,et al.  Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. , 2010, Current drug targets.

[39]  R. Kurzrock,et al.  Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? , 2010, The oncologist.

[40]  Kenneth P. Roos,et al.  Autocrine VEGF Signaling Is Required for Vascular Homeostasis , 2007, Cell.

[41]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[42]  J. Bruix,et al.  Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.